• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
IMS Pharmaceutical Country Review 2013: Indonesia - Product Image

IMS Pharmaceutical Country Review 2013: Indonesia

  • Published: August 2013
  • Region: Indonesia
  • 75 Pages
  • IMS Health

IMS Pharmaceutical Country Review 2013: Indonesia provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years. Sales performance is analysed in terms of major corporations, therapeutic classes, major products and new product activity.

Section 1:

The first section provides a synopsis of the healthcare system and relevant pharmaceutical issues is based on primary research gathered by the IMS country experts.

Section 2:

The standardised comparable data against which the industry is measured stems from accurate and reliable IMS audited year end sales data. This can be found in the country performance section which features a series of figures, including useful measures:

- US$ sales
- 5 year growth in US$ and local currency dollar (eliminating inaccuracies due to exchange rate fluctuations)
- Evolution Index
- Market share

Data included to the end of 2012.

Section 3:

A detailed information file allowing a thorough understanding of the data values and definitions, the universe/country abbreviations, and the EphMRA anatomical therapeutic classification can be found in the Appendices section.

Section 1: Synopsis of the Healthcare Market

1. Market Trends

2. Healthcare Provision

3. Prescribing Policy

4. Pricing System

5. Regulatory Environment

6. Industry Environment

7. Channels of Distribution

Section 2: Country Sales Performance and Trends

Figure 1: Country Ranking amongst 30 Markets Worldwide
Figure 2: Audited Market Trend
Figure 3: Leading 35 Local Companies
Figure 4: Leading 35 Corporations
Figure 5: Market Share By Corporate Nationality
Figure 6: Leading 15 Therapeutic Classes (Level 3) 2012
Figure 7: 15 Fastest-Growing Therapeutic Classes (Level 3) 2012
Figure 8-22: Leading 15 Therapeutic Class Profiles
Figure 8: A2A ANTACIDS ANTIFLATULENTS
Figure 9: A2B ANTIULCERANTS
Figure 10: A7F ANTIDIARR MICRO-ORGANISM
Figure 11: A10X OTHER DRUGS FOR DIABETES
Figure 12: C8A CALCIUM ANTAGONIST PLAIN
Figure 13: J1C BROAD SPECTR.PENICILLINS
Figure 14: J1D CEPHALOSPORINS & COMBS
Figure 15: J7A PURE VACCINES
Figure 16: J7B COMBINATIONS OF VACCINES
Figure 17: K1B STANDARD SOLUTIONS
Figure 18: M1A ANTIRHEUMATIC N-STEROID
Figure 19: N2B NON-NARCOTIC ANALGESICS
Figure 20: R5A COLD PREPARATIONS
Figure 21: R5F OTHER COUGH & COLD PREPS
Figure 22: V3X ALL OTH.THERAPEUTIC PRDS
Figure 23: Leading 40 Products
Figure 24: Leading 40 New Products
Figure 25: Leading 15 Product Forms
Figure 26: Fastest Growing 40 Products Sales Trends

Section 3: Appendices

Appendix 1: Audited Universe
Appendix 2: Country Specific Alerts
Appendix 3: Measure Index
Appendix 4: Sales Data Measures
Appendix 5:*Latest Factors
Appendix 6: Quarterly US$ Exchange Rates By Country
Appendix 7: Corporations
Appendix 8: Product Names
Appendix 9: Therapies
Appendix 10: EphMRA Anatomical Therapeutic Classification

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos